- Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease - - Prasinezumab is a potential ...

Despite their differences, Alzheimer’s disease and Parkinson’s disease share several risk factors and mechanisms of neuronal damage. Both also feature a phase that precedes the appearance of symptoms ...

ST. PAUL, Minn., April 11 (UPI) --Israeli researchers said Friday they have developed a simple, "revolutionary" blood test that for the first time would allow doctors to detect the onset of ...

Please provide your email address to receive an email when new articles are posted on . Dopamine agonists target D2/D3 receptors, possibly increasing adverse events. Tavapadon targets D1/D5 receptors, ...

Up to 1 in 3 people with Parkinson's disease use at least one psychotropic medication, a recent study from the University of Eastern Finland shows. People with Parkinson's disease were using ...

Your T cells work hard to fight disease. Unfortunately, "friendly fire" from T cells can sometimes harm the body's healthy tissues. For people with autoimmune disease, T cell reactivity is a big ...

A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson's disease in its earliest stages, before extensive brain damage has ...

A team led by researchers at Chalmers University of Technology has succeeded in identifying biomarkers for Parkinson's disease in its earliest stages – before extensive brain damage has occurred. The ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, ...

Up to one in three people with Parkinson’s disease use at least one psychotropic medication, a recent study from the University of Eastern Finland shows. People with Parkinson’s disease were using ...